1225441-13-3

Basic information

• Product Name: 2-bromo-N-(4-nitro-3-(trifluoromethyl)phenyl)-2-methylpropanamide
• Synonyms: 2-bromo-N-(4-nitro-3-(trifluoromethyl)phenyl)-2-methylpropanamide
• CAS NO: 1225441-13-3
• Molecular Weight: 355.111
• Mol File: 1225441-13-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-bromo-N-(4-nitro-3-(trifluoromethyl)phenyl)-2-methylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N-(4-nitro-3-(trifluoromethyl)phenyl)-2-methylpropanamide(1225441-13-3)
• EPA Substance Registry System: 2-bromo-N-(4-nitro-3-(trifluoromethyl)phenyl)-2-methylpropanamide(1225441-13-3)

Safety Data

• Hazardous Substances Data: 1225441-13-3(Hazardous Substances Data)

Upstream product

• 594-34-3 1,2-dibromo-2-methyl-propane 
• 393-11-3 4-nitro-3-(trifluoromethyl)benzeneamine 
• 2052-01-9 2-bromo-2-methylpropionic acid 

Relevant articles and documents

Silver-Promoted Fluorination Reactions of α-Bromoamides

Silver-promoted C?F bond formation in α-bromoamides by using AgF under mild conditions is reported. This simple method enables access to tertiary, secondary, and primary alkyl fluorides involving biomolecular scaffolds. This transformation is applicable to primary and secondary amides and shows broad functional-group tolerance. Kinetics experiments revealed that the reaction rate increased in the order of 3°>2°>1° α-carbon atom. In addition, it was found that the acidic amide proton plays an important role in accelerating the reaction. Mechanistic studies suggested generation of an aziridinone intermediate that undergoes subsequent nucleophilic addition to form the C?F bond with stereospecificity (i.e., retention of configuration). The synthesis of sterically hindered alcohols and ethers by using AgI is also demonstrated. Examples of reactions of α-bromoamides with O nucleophiles are presented.

Method of treatment for prostatic cancer

Disclosed is a new treatment for men with prostatic cancer involving combination therapy of a 5α-reductase inhibitor, i.e., a 17β-substituted 4-azasteroid, a 17β-substituted non-azasteroid, 17β-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an antiandrogen, i.e. flutamide. Pharmaceutical compositions useful for treatment are also disclosed.